Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IPSS Risk Category Intermediate-2”

32 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 32 results

Testing effectiveness (Phase 2)UnknownNCT00885508
What this trial is testing

The Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaAcute Myeloid Leukemia
Groupe Francophone des Myelodysplasies 85
Testing effectiveness (Phase 2)Study completedNCT01584531
What this trial is testing

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromeMDSTrisomy 8
Traws Pharma, Inc. 82
Testing effectiveness (Phase 2)Ended earlyNCT02010645
What this trial is testing

Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 6
Early research (Phase 1)WithdrawnNCT02075034
What this trial is testing

Three Dosing Schedules of Oral Rigosertib in MDS Patients

Who this might be right for
Myelodysplastic Syndrome
Traws Pharma, Inc.
Large-scale testing (Phase 3)Ended earlyNCT02158936
What this trial is testing

Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Thrombocytopaenia
Novartis Pharmaceuticals 356
Testing effectiveness (Phase 2)UnknownNCT00424229
What this trial is testing

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 49
Testing effectiveness (Phase 2)Study completedNCT01692366
What this trial is testing

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Who this might be right for
Myelofibrosis
Bristol-Myers Squibb 8
Testing effectiveness (Phase 2)Study completedNCT02016781
What this trial is testing

Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)

Who this might be right for
MDS
Medical College of Wisconsin 384
Testing effectiveness (Phase 2)Study completedNCT00451048
What this trial is testing

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Who this might be right for
Chronic Myelomonocytic Leukemiade Novo Myelodysplastic SyndromesMyelodysplastic Syndromes+1 more
National Cancer Institute (NCI) 10
Not applicableStudy completedNCT05218902
What this trial is testing

Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Bristol-Myers Squibb 290
Testing effectiveness (Phase 2)UnknownNCT00022321
What this trial is testing

Gemtuzumab in Treating Patients With Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndromes
Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)Study completedNCT02426086
What this trial is testing

Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

Who this might be right for
Myelofibrosis
Geron Corporation 107
Early research (Phase 1)Looking for participantsNCT07469891
What this trial is testing

PRT12396 in Participants With Select Myeloproliferative Neoplasms

Who this might be right for
Polycythemia Vera (PV)Myelofibrosis (MF)Myeloproliferative Neoplasms (MPNs)+3 more
Prelude Therapeutics 100
Testing effectiveness (Phase 2)Study completedNCT00776503
What this trial is testing

Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 52
Testing effectiveness (Phase 2)Study completedNCT00531232
What this trial is testing

A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic SyndromesSecondary Acute Myeloid Leukemia (AML)
Genzyme, a Sanofi Company 38
Testing effectiveness (Phase 2)WithdrawnNCT00867061
What this trial is testing

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome
Traws Pharma, Inc.
Large-scale testing (Phase 3)Active Not RecruitingNCT04576156
What this trial is testing

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Who this might be right for
Myelofibrosis
Geron Corporation 327
Large-scale testing (Phase 3)Study completedNCT04617028
What this trial is testing

Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

Who this might be right for
Myelofibrosis
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 105
Testing effectiveness (Phase 2)Not Yet RecruitingNCT02944955
What this trial is testing

BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Who this might be right for
Myelodysplastic Syndrome (MDS)
BioLite, Inc. 52
Not applicableStudy completedNCT00987584
What this trial is testing

Phase II Cont. IV of ON 01910.Na in MDS w/ Trisomy 8/Intermed-1, 2/High Risk

Who this might be right for
Myelodysplastic Syndromes
Peter L Greenberg 13
Load More Results